 This study found no significant difference in the outcome of mild-to-moderate immunologically risk kidney transplants between those who received induction therapy with thymoglobulin or basaliximab. Both induction therapies had similar results in terms of acute rejection episodes, serum creatinine levels, and graft survival. This article was authored by Haytam Ali, Mamoud Mohammed, T-Bofulop, and others.